000181300 001__ 181300
000181300 005__ 20240229145644.0
000181300 0247_ $$2doi$$a10.1038/s41416-022-01932-1
000181300 0247_ $$2pmid$$apmid:35986087
000181300 0247_ $$2ISSN$$a0007-0920
000181300 0247_ $$2ISSN$$a1532-1827
000181300 0247_ $$2altmetric$$aaltmetric:134775838
000181300 037__ $$aDKFZ-2022-01927
000181300 041__ $$aEnglish
000181300 082__ $$a610
000181300 1001_ $$aTomczak, Aurelie$$b0
000181300 245__ $$aPrecision oncology for intrahepatic cholangiocarcinoma in clinical practice.
000181300 260__ $$aEdinburgh$$bNature Publ. Group$$c2022
000181300 3367_ $$2DRIVER$$aarticle
000181300 3367_ $$2DataCite$$aOutput Types/Journal article
000181300 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1666967173_11984
000181300 3367_ $$2BibTeX$$aARTICLE
000181300 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181300 3367_ $$00$$2EndNote$$aJournal Article
000181300 500__ $$a2022 Nov;127(9):1701-1708
000181300 520__ $$aAdvanced cholangiocarcinoma has a poor prognosis. Molecular targeted approaches have been proposed for patients after progression under first-line chemotherapy treatment. Here, molecular profiling of intrahepatic cholangiocarcinoma in combination with a comprehensive umbrella concept was applied in a real-world setting.In total, 101 patients received molecular profiling and matched treatment based on interdisciplinary tumour board decisions in a tertiary care setting. Parallel DNA and RNA sequencing of formalin-fixed paraffin-embedded tumour tissue was performed using large panels.Genetic alterations were detected in 77% of patients and included gene fusions in 21 patients. The latter recurrently involved the FGFR2 and the NRG1 gene loci. The most commonly altered genes were BAP1, ARID1A, FGFR2, IDH1, CDKN2A, CDKN2B, PIK3CA, TP53, ATM, IDH2, BRAF, SMARCA4 and FGFR3. Molecular targets were detected in 59% of patients. Of these, 32% received targeted therapy. The most relevant reason for not initiating therapy was the deterioration of performance status. Patients receiving a molecular-matched therapy showed a significantly higher survival probability compared to patients receiving conventional chemotherapy only (HR: 2.059, 95% CI: 0.9817-4.320, P < 0.01).Molecular profiling can be successfully translated into clinical treatment of intrahepatic cholangiocarcinoma patients and is associated with prolonged survival of patients receiving a molecular-matched treatment.
000181300 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000181300 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181300 7001_ $$aSpringfeld, Christoph$$b1
000181300 7001_ $$0P:(DE-He78)54a6641a6c26ddc49cc754740e90b438$$aDill, Michael T$$b2$$udkfz
000181300 7001_ $$aChang, De-Hua$$b3
000181300 7001_ $$00000-0001-8187-3281$$aKazdal, Daniel$$b4
000181300 7001_ $$aWagner, Ursula$$b5
000181300 7001_ $$aMehrabi, Arianeb$$b6
000181300 7001_ $$aBrockschmidt, Antje$$b7
000181300 7001_ $$00000-0002-6288-8821$$aLuedde, Tom$$b8
000181300 7001_ $$aNaumann, Patrick$$b9
000181300 7001_ $$aStenzinger, Albrecht$$b10
000181300 7001_ $$aSchirmacher, Peter$$b11
000181300 7001_ $$00000-0001-8888-1030$$aLongerich, Thomas$$b12
000181300 773__ $$0PERI:(DE-600)2002452-6$$a10.1038/s41416-022-01932-1$$n9$$p1701-1708$$tBritish journal of cancer$$v127$$x0007-0920$$y2022
000181300 909CO $$ooai:inrepo02.dkfz.de:181300$$pVDB
000181300 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)54a6641a6c26ddc49cc754740e90b438$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000181300 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000181300 9141_ $$y2022
000181300 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000181300 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000181300 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000181300 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J CANCER : 2021$$d2022-11-15
000181300 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-15
000181300 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-15
000181300 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-15
000181300 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-15
000181300 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-15
000181300 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-15
000181300 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-15
000181300 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-15
000181300 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-15
000181300 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J CANCER : 2021$$d2022-11-15
000181300 9201_ $$0I:(DE-He78)F240-20160331$$kF240$$lNWG Experimentelle Hepatologie, Entzündung und Krebs$$x0
000181300 980__ $$ajournal
000181300 980__ $$aVDB
000181300 980__ $$aI:(DE-He78)F240-20160331
000181300 980__ $$aUNRESTRICTED